Thrombotic Microangiopathy-Kidneys and Beyond: Historic Lessons

Abbreviations: TTP: Thrombotic Thrombocytopenic Purpura; TMA: Thrombotic Microangiopathy; HUS: Hemolytic Uremic Syndrome; MAC: Membrane-Attack-Complex; vWF: von Willebrand Factor

Editorial

The first description of the condition, belonging to the continuum of thrombotic microangiopathies, was published 1924, when Moschcowitz reported a case of acute febrile anemia with petechiae, renal involvement and hyalin thrombosis of the terminal arterioles and capillaries in an adolescent girl [1,2]. The next case, reported by Baehr and co-workers in 1936, presented with reticulocytosis and thrombocytopenia in addition to severe anemia [3]. In 1947 Singer and co-workers suggested the name “Thrombotic thrombocytopenic purpura” (TTP) to describe similar cases, published next decade [4]. In 1950 Gore described the histology pattern in TTP as disseminated arteriolar and capillary platelet thrombosis, and Symmers in 1952 introduced the term “thrombotic microangiopathy” (TMA) for this pattern of injury [5,6]. A few years later, in 1955, Belnap and O’Donnell found that most severe cases of epidemic diarrhea, induced by specific strain of E Coli in children, were associated with purpura, anuria, and neurologic signs. Autopsy material revealed thrombosis of capillary and precapillary arterioles in lungs, liver, brain, and kidneys, as well as glomerular tuft occlusion by fibrin thrombi [7].

Same year Gasser and co-workers reported bilateral necrosis of the renal cortex in acute acquired hemolytic anemia in children, and named it “Hemolytic-uremic syndrome” (HUS) [8]. The syndrome, described by Gasser, was in respects similar to that was reported by Moschowitz and Baehr and later named TTP, nevertheless he considered HUS different from TTP because of name presence of renal failure. However, it was shown by Habib and Pong and co-authors in 1982, that the fundamental pathologic lesion - TMA, is identical in HUS and TTP although it can preferentially involve different organs [9,10]. It was described also that patients with clinical diagnosis of HUS can manifest with neurologic involvement, and a high percentage of patients, classified as having TTP, had renal failure. Moreover, individual patients have been reported as having HUS in one episode and TTP during another [11-16].

This paradox aroused because the pathogenesis of TTP and HUS at that time remained unexplained, despite some facts, which later gave a clue, were already cumulated. In 1965 a combination of hemolytic anemia and azotemia was described in concordant monozygous twins, and since that time, familial HUS has been reported in children, and, infrequently in adults, with both autosomal dominant and recessive patterns of inheritance [17,18]. In 1970-th it was found, that early complement components in patients with HUS may be reduced, but terminal membrane-attack-complex (MAC) of complement generally is spared. It was also shown that patients with HUS, who have low C3 levels have high levels of activated complement components, including C3b, C3c, and C3d. Deposits of C3, found in glomeruli and arterioles, consistent with the activation of complement and local C3 consumption, and C9 staining in glomeruli and small arteries with intimal proliferation and thrombosis documents activation up to the terminal lytic MAC [19-26]. Same period the role for abnormalities in von Willebrand factor (vWF) metabolism and interaction between platelets and large vWF multimers was suggested in the pathogenesis of HUS/TTP [27-30].

In the early 1980-th it was found that E coli of certain strains produce Shiga-like cytotoxins, E. coli 0157:H7 produces Shiga-like toxin/verotoxin, causes haemorrhagic colitis, and is associated with sporadic cases of “classical”, or so called diarrhea associated (D+) HUS of children, thereby the link between Shiga-like toxin (Stx)-producing E Coli and D+ HUS was established [31-33] To this end in 1983 Wardle, revising TMA’s, described HUS and TTP as distinct entities [34]. However, basing on the overlap in clinical signs and symptoms and common pathology of TTP and HUS, Remuzzi, discussing these issues in 1987, declared: “In the absence of criteria, that can differentiate between HUS and TTP, I favor the view that these term describe different clinical expressions of the same disease, a disease, characterized by microangiopathy, hemolytic anemia, renal failure and, sometimes, neurologic involvement. A diagnosis of this disease, which I shall term HUS/TTP, should be entertained whenever acute hemolytic anemia of the microangiopathic type is associated with thrombocytopenia and any degree of renal damage” [35].

The new facts were accumulated next decade, and at the turn of millennium became clear, that most cases of HUS (including more than 90% of those in children) are secondary to infection with Escherichia coli serotype O157:H7 and some others, which produce Stx. Term D+ HUS therefore was replaced by the term Shiga-toxin Escherichia coli (STEC) associated HUS. It was found,
however; that HUS may be associated also with several other bacteria, such as *Streptococcus pneumoniae*; and approximately 10% of cases of the hemolytic-uremic syndrome were classified as diarrhea-negative/non-diarrhea-associated HUS (D- HUS). Later on the term atypical HUS (aHUS) was introduced to distinguish cases not caused by either Stx-producing bacteria or streptococci [36-38]. Genetic abnormalities in several complement system proteins have been documented in the familial form of aHUS: loss-of-function mutation in a regulatory gene of Factor H and Factor I, or a gain-of-function mutation in an effector gene of Factor B or C3. In addition to genetic abnormalities, a functional deficiency in complement Factor H may develop in presence of antibodies to the complement, resulting in acquired TMA [39,40]. Sporadic cases of aHUS were described in association with infection with the human immunodeficiency virus, cancer, organ transplantation, pregnancy, and the use of certain drugs [41].

At the same time the role of the protease, cleaving the ultra-large vWF (ULvWF) multimers and preventing inappropriate platelet adhesion and thrombosis, was demonstrated. In the absence of this protease ULvWF are not cleaved, causing intravascular platelet thrombosis of TTP. This protease was identified as A Disintegrin-like And Metalloprotease with a ThromboSpondin type 1 motif 13 (ADAMTS13); the gene for vWF-cleaving protease ADAMTS13 was mapped to chromosome 9q34 and 12 mutations in patients with TTP were identified; and the role of anti-ADAMTS13 antibodies that inhibit the proteolytic activity of ADAMTS13 in acquired TTP was confirmed. Based on these findings the concept of TTP as state of dysfunction or deficiency in ADAMTS13, was accepted [42-46].

With that knowledge of aHUS and TTP pathogenesis mechanisms in mind, Tsai in 2003 postulated: "The term TTP/ HUS should be avoided because it obscures differences among the various types of TMA" [47]. During the last decade huge progress in the understanding of molecular mechanisms of STEC-HUS, aHUS, TTP and other forms of TMA was made; the role of genetic abnormalities, autoimmunity, and infection and their interactions was demonstrated; and several classification systems of TMA were proposed. One suggests that we have to distinguish only the key point in the diagnosis of TMA as a first step is to evaluate clinical sings and symptoms. TMA is diagnosed in presence of thrombocytopenia, microangiopathic hemolysis (negative Coombs test, hystocytosis, reticulocytosis, elevated LDH, low haptoglobin) and severe organ/multiorgan damage. As a second step, differential diagnostics of primary TMA syndromes and common TMA-associated disorders demand careful evaluation of current illness and family history, concurrent diseases, drug history, coagulation tests, autoimmunity screening, serum complement levels, stools for STEC and ADAMTS13 plasma activity test. Accurate diagnosis guides proper treatment for TMA-associated life-threatening conditions, which currently available for many TMA syndromes, including aHUS and TTP.

**References**


